11027 results for 'cell viability assay'

A depletion experiment is only as good as the depletion you can prove. Injecting a functional-grade antibody and assuming the population is gone is the most common failure mode in in vivo immunology.

Secondary Antibodies | HRP, FITC, Cy3 & AP Conjugates | Assay Genie

Complete T Helper Cell Guide: Th1, Th2, Th17 & Functions - Your Ultimate Resource from Assay GenieIn this guide, we will explore the differences between TH1 and TH2 cells, their crucial r

Immunology Guide MHC Class I vs Class II: Key Differences & Functions [Guide] Major Histocompatibility Complex molecules present antigens to T

What You Need to Know About PolatuzumabWhat is Polatuzumab??Polatuzumab vedotin is an antibody-drug conjugate targeting CD79b, a component of the B-cell receptor, used primarily in B-cel

The initial identification of PD-1 as a potential target for cancer treatment occurred in the late 1990s and early 2000s through studies exploring the regulation of T-cell responses.

Introduction to KIR Blockade in Cancer ImmunotherapyNatural killer (NK) cells are crucial components of the innate immune system, responsible for recognizing and destroying virally infec

COVID-19 Schnelltest (Pflegepunkt) Beschreibung                       Das Assay Genie COVID-19 POC Sc

Site-Directed Mutagenesis | Protocol, Kits & Troubleshooting | Assay Genie

Biochemistry · Cell SignallingPhosphorylation: Types, ATP Synthesis and Cell SignallingAdding a phosphate group is how cells both store energy and switch proteins on and off. The same chemistry underl

Extracellular Vesicles

Non-Small Cell Lung Carcinoma (NSCLC) is the most common type of lung cancer, representing about 85% of all lung cancer cases. NSCLC includes several subtypes, with distinct biological ch

Dendritic cells (DCs) are pivotal in the immune system, orchestrating innate and adaptive immune responses. Understanding their developmental lineage pathway is crucial in immunology, particularly

The fight against B cell cancers, a challenging spectrum of hematologic malignancies, has entered a new era with the introduction of rituximab biosimilars. These biosimilars promise to extend the

CD25, a key molecule in immune regulation, is integral to the function of activated lymphocytes and regulatory T cells. It's central in mediating immune responses, with implications in autoimmune